InMed Pharmaceuticals, Inc.

As of September 23, 2022, InMed Pharmaceuticals, Inc. is considered a risky investment due to its negative P/E ratio, poor return metrics, and significant year-to-date stock decline of -50.21%, indicating it may be overvalued compared to peers like Plus Therapeutics, Inc.

As of September 23, 2022, InMed Pharmaceuticals, Inc. is considered risky and overvalued with poor financial metrics, including a price to book value of 0.49 and a negative ROE of -118.37%, significantly underperforming its peers and the S&P 500.

As of June 11, 2025, InMed Pharmaceuticals, Inc. is in a mildly bearish trend due to daily moving averages indicating bearish momentum, despite some mixed signals from weekly indicators suggesting caution in the market.

As of March 2022, the management team of InMed Pharmaceuticals, Inc. includes Dr. William Garner (Independent Chairman), Mr. Eric Adams (President and CEO), and Independent Directors Mr. Adam Cutler, Mr. Andrew Hull, and Ms. Catherine Sazdanoff. They oversee the company's strategic direction and operations.

InMed Pharmaceuticals, Inc. is a pre-clinical-stage biopharmaceutical company focused on developing cannabinoid-based therapies. As of March 2025, it has a market cap of $2.85 million, with net sales of $1 million and a net loss of $2 million.

As of Jun 18, InMed Pharmaceuticals, Inc. has a market capitalization of 2.85 million, categorizing it as a Micro Cap company, with net sales of 4.91 million and a net profit loss of 8.32 million over the last four quarters. As of June 2024, the company reported shareholder's funds of 9.21 million and total assets of 11.82 million.